707 860
[38]
Bernard Jr JR, Buskirk SJ, Heckman MG, et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatec- tomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010;76:735–40.
[39]
Blanchard P, Bakkour M, De Crevoisier R, et al. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. Urol Oncol 2015;33:108.e15-20.
[40]
Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with bio- chemical recurrence after radical prostatectomy. Eur Urol 2014; 66:479–86.
[41]
Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011;117:3925–32.
[42]
Ervandian M, Hoyer M, Petersen SE, et al. Salvage radiation thera- py following radical prostatectomy. A national Danish study. Acta Oncol 2016;55:598–603.
[43]
Fossati N, Karnes RJ, Cozzarini C, et al. Assessing the optimal timing for early salvage radiation therapy in patients with pros- tate-specific antigen rise after radical prostatectomy. Eur Urol 2016;69:728–33.
[44]
Goenka A, Magsanoc JM, Pei X, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 2012;84:112–8.
[45]
Jackson W, Hamstra DA, Johnson S, et al. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radia- tion therapy following radical prostatectomy. Cancer 2013;119: 3287–94.
[46]
Kwon O, Kim KB, Lee YI, et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One 2014;9:e103574.
[47]
Lohm G, Lutcke J, Jamil B, et al. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical pros- tatectomy: long-term follow-up of a single-center survey. Strah- lenther Onkol 2014;190:727–31.
[48]
Moreira DM, Jayachandran J, Presti Jr JC, et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int 2009;104:1452–6.
[49]
Ost P, Lumen N, Goessaert AS, et al. High-dose salvage intensity- modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate- specific antigen: 5-year results. Eur Urol 2011;60:842–9.
[50]
Parekh A, Chen MH, Graham P, et al. Role of androgen deprivation therapy in early salvage radiation among patients with prostate- specific antigen level of 0.5 or less. Clin Genitourin Cancer 2015;13:e1–6.
[51]
Ploussard G, Staerman F, Pierrevelcin J, et al. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prosta- tectomy: results from a national multicentre study. World J Urol 2014;32:1331–8.
[52]
Siegmann A, Bottke D, Faehndrich J, et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progres- sion-free survival: results of a retrospective study. Strahlenther Onkol 2011;187:467–72.
[53]
Song W, Jeon HG, Sung HH, et al. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy. Int J Urol 2016;23:56–61.
[54]
Stish BJ, Pisansky TM, HarmsenWS, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy inmen with detectable prostate-specific antigen after prostatectomy for pros- tate cancer. J Clin Oncol 2016;34:3864–71.
[55]
Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radio- therapy after radical prostatectomy. J Clin Oncol 2016;34: 3648–54.
[56]
Umezawa R, Ariga H, Ogawa Y, et al. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 n g/ml. Radiat Oncol 2011;6:150.
[57]
van der Poel HG, Tillier C, de Blok W, Acar C, van Muilekom EH. Salvage radiotherapy after robot-assisted laparoscopic radical prostatectomy. Urology 2013;82:834–8.
[58]
Fiorino C, Broggi S, Fossati N, et al. Predicting the 5-year risk of biochemical relapse after postprostatectomy radiation therapy in PT2, pN0 patients with a comprehensive tumor control proba- bility model. Int J Radiat Oncol Biol Phys 2016;96:333–40.
[59]
Sia M, Rodrigues G, Menard C, et al. Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. Can Urol Assoc J 2010;4:105–11.
[60]
Ost P, Fonteyne V, Villeirs G, Lumen N, Oosterlinck W, De Meerleer G. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 2009;56:669–75.
[61]
Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009;93:207–12.
[62]
Cozzarini C, Fiorino C, Da Pozzo LF, et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys 2012;82:191–9.
[63]
Sowerby RJ, Gani J, Yim H, Radomski SB, Catton C. Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Can Urol Assoc J 2014;8:253–8.
[64]
Hegarty SE, Hyslop T, Dicker AP, Showalter TN. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. PLoS One 2015;10:e0118430.
[65]
Showalter TN, Hegarty SE, Rabinowitz C, et al. Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. Int J Radiat Oncol Biol Phys 2015;91:752–9.
[66]
Cozzarini C, Fiorino C, Deantoni C, et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 2014;66:1024–30.
[67]
Goenka A, Magsanoc JM, Pei X, et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 2011;60: 1142–8.
[68]
Cremers RG, van Lin EN, Gerrits WL, et al. Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy. Radiother Oncol 2010;97:467–73.
[69]
Jereczek-Fossa BA, Ciardo D, Ferrario S, et al. No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. Br J Radiol 2016;89: 20150985.
[70]
Van Praet C, Ost P, Lumen N, et al. Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. Radiother Oncol 2013;109:222–8.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 8 9 – 7 0 9
707